

Repertorio n. 1405/2021 Prot n. 296657 del 09/11/2021

DECRETO DEL DIRIGENTE

Oggetto: G007_2021 Procedura Aperta D. Lgs 50/2016 art. 60, comma 1, per Accordo Quadro per il servizio di Clinical Research Organisation (CRO) relativo agli studi (sperimentazioni) no profit di cui è, o sarà, promotore il Dipartimento di Scienze Biomediche Sperimentali e Cliniche "Mario Serio" dell'Università degli Studi di Firenze, della durata di anni 4 (quattro), con possibilità di rinnovo, aggiudicato in base al criterio dell'offerta economicamente più vantaggiosa, ai sensi dell'art. 95 D.lgs. 50/2016 e ss.mm.ii. CIG 8892845FD5. Decreto di nomina Commissione Giudicatrice ex art. 77 DLgs 50/2016

IL DIRIGENTE

VISTO il d.lgs. 18 aprile 2016 n. 50 recante "*Codice dei contratti*" e relative linee guida;

VISTO lo Statuto dell'Università degli Studi di Firenze;

VISTO il Regolamento di Amministrazione, Finanza e Contabilità dell'Università degli Studi di Firenze;

RICHIAMATO il Decreto del Direttore Generale n. 67/2021 prot. 15666 del 15/01/2021 contenente delega alla sottoscrizione degli atti della Centrale Acquisti;

VISTA la normativa vigente in materia di anticorruzione e trasparenza, il Piano Triennale per la Prevenzione della Corruzione e della Trasparenza dell'Università degli Studi di Firenze e il Decreto rettorale del 8 febbraio 2016, n. 98 - Codice di comportamento dell'Università degli Studi di Firenze;

RICHIAMATA la determina dirigenziale Rep. n. 1376/2021 Prot. n. 291487 del 04/11/2021, pubblicata in Albo ufficiale di Ateneo rep. 12749/2021 - Prot. n. 0291498 del 04/11/2021, di ammissione/esclusione dei concorrenti alla successiva fase di gara di apertura e valutazione delle offerte tecniche ed economiche relative all'affidamento di cui in epigrafe mediante stipula di un Accordo Quadro, ex art. 54 co. 3 del d.lgs. 50/2016, nonché sul profilo della Stazione Appaltante www.unifi.it sezione Bandi di Gara;

VALUTATA la qualificazione, anche mediante esame dei *curricula*, dei seguenti soggetti ai fini della nomina a componente della Commissione Giudicatrice:

- 1) Prof.ssa Monica Mangoni - Professore Associato, SSD MED36 (Diagnostica per Immagini e Radioterapia), Sezione di Radioterapia, Dipartimento di Scienze Biomediche

Sperimentali e Cliniche “Mario Serio”, Università di Firenze e Dirigente Medico I livello, SOD Radioterapia, DAI Oncologia, Azienda Ospedaliero-Universitaria Careggi, Firenze;

2) Dott. Andrea Morandi - Ricercatore, BIO/10 – Biochimica, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze;

3) Prof. Icro Meattini - Professore Associato MED/36 - Diagnostica per immagini e radioterapia Sezione di Radioterapia, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze.

RITENUTO OPPORTUNO nominare segretario verbalizzante la Dott.ssa Sara Del Santo - Funzionario Amministrativo, afferente alla Centrale Acquisti, Università di Firenze e come segretario supplente la Dott.ssa Renata Mastracca - Funzionario Amministrativo, afferente al Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze;

RICEVUTA la disponibilità dei suddetti allo svolgimento dell’incarico;

ACQUISITE le dichiarazioni (conservate agli atti) dei nominandi commissari da cui risulta, con riferimento agli operatori economici che hanno rimesso offerta, che non sussistono cause di conflitto d’interesse e di incompatibilità ai sensi degli artt. 42 e 77 del D.Lgs. 50/2016, dell’art. 51 del cod. proc. civ., dell’art. 35 bis del D.Lgs. 165/01;

RITENUTO di dare attuazione alle disposizioni legislative di cui agli artt. 29, comma 1 del D. Lgs 50/2016 e 76 co. 2 bis del d.lgs. 50/2016 e dell’art. 5 bis del codice dell’amministrazione digitale, di cui al decreto legislativo 7 marzo 2005, n. 82, mediante pubblicazione del presente provvedimento e dei curricula allegati prodotti dai membri della commissione giudicatrice, sul profilo del committente Unifi, nella sezione Bandi di gara nonché sull’Albo on line della stazione appaltante;

DATO ATTO che tutti gli atti della presente procedura di gara, oltre che sul sistema telematico START e il profilo committente, sono disponibili anche presso l’Ufficio Centrale Acquisti dell’Università degli Studi di Firenze, via Capponi n.7 primo piano;

ciò premesso,

DECRETA

- a) La nomina, ai fini della valutazione delle offerte presentate, relative all’Accordo Quadro in oggetto, della seguente Commissione Giudicatrice, ai sensi dell’art. 77 d.lgs. 50/2016:
 - 1) Presidente Commissione di gara: Prof.ssa Monica Mangoni - Professore Associato, SSD MED36 (Diagnostica per Immagini e Radioterapia), Sezione di Radioterapia, Dipartimento di Scienze Biomediche Sperimentali e Cliniche



- “Mario Serio”, Università di Firenze e Dirigente Medico I livello, SOD Radioterapia, DAI Oncologia, Azienda Ospedaliero-Universitaria Careggi, Firenze;
- 2) Membro della Commissione: Dott. Andrea Morandi - Ricercatore, BIO/10 – Biochimica, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze;
 - 3) Membro della Commissione: Prof. Icro Meattini - Professore Associato MED/36 - Diagnostica per immagini e radioterapia Sezione di Radioterapia, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze;
 - 4) Segretario verbalizzante: Dott.ssa Sara Del Santo - Funzionario Amministrativo, afferente alla Centrale Acquisti, Università di Firenze
 - 5) Segretario supplente: Dott.ssa Renata Mastracca - Funzionario Amministrativo, afferente al Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze;

I componenti della Commissione non potranno svolgere alcun'altra funzione o incarico tecnico o amministrativo relativamente ai contratti di che trattasi, fermo restando che nessun compenso è riconosciuto per lo svolgimento dell'incarico.

- b) di dare atto che tutti gli atti e documenti della presente procedura di gara, sono conservati digitalmente nel sistema telematico START e nel profilo committente, oltre che disponibili presso l'Ufficio Centrale Acquisti dell'Università degli studi di Firenze, via Capponi 7 primo piano;
- c) di procedere alla pubblicazione del presente provvedimento e relativi curricula allegati sul profilo del committente nella sezione bandi di gara, nonché sull'Albo on line della stazione appaltante, ai sensi e per gli effetti dell'art. 29 D. Lgs 50/2016;

f.to IL DIRIGENTE
Dott. Massimo Benedetti

Allegati:

1. Curricula Commissari

Monica Mangoni

CURRICULUM VITAE

Posizione attuale *Dal 1 novembre 2015:* Professore Associato, SSD MED36 (Diagnostica per Immagini e Radioterapia) , Sezione di Radioterapia, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze. Dirigente Medico I livello, SOD Radioterapia, DAI Oncologia, Azienda Ospedaliero-Universitaria Careggi, Firenze

Posizioni lavorative precedenti *Dal 16 febbraio 2009 al 31 ottobre 2015:* Ricercatore di Ruolo, SSD MED36 (Diagnostica per Immagini e Radioterapia) , Sezione di Radioterapia, Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze . Ricercatore di Ruolo Confermato dal 18 febbraio 2012. Dirigente Medico I livello, SOD Radioterapia, DAI Oncologia, Azienda Ospedaliero-Universitaria Careggi, Firenze

Formazione *24 ottobre 2001,* Laurea in Medicina e Chirurgia, Università degli Studi di Firenze, massimo dei voti con lode, *11 dicembre 2006.* Specializzazione in Radioterapia, Università degli Studi di Firenze, Massimo di voti con lode *7 maggio 2010.* Conseguito il titolo di Dottore di Ricerca in Scienze Endocrinologiche e Metaboliche, Università degli Studi di Firenze e in “Sciences de la Vie, Biologie, Santé”, disciplina “Radiobiologie,” , ED 418 “Cancérologie Biologie Médecine Santé”, Università Paris XI Sud, Parigi, Francia con il voto di Très Honorable .

Esperienze all'estero *Settembre 2004-dicembre 2006.* stage al Laboratoire de Radiosensibilité des Tumeurs et des Tissus Sains UPRES EA 27-10 all'Institut Gustave Roussy, Villejuif (Francia)

Premi scientifici e riconoscimenti 2nd ESTRO Forum (European Society for Radiotherapy and Oncology) Aprile 2013 Ginevra, *Premio Poster* per il track Radiobiologia; 19th AIRO (Società Italiana Radioterapia Oncologica) novembre 2009 Bologna, *Premio Poster*; ENDO 2009 (The Endocrine Society) giugno 2009 Washington, *Premio Poster*; 18th SFRO (Société Française de Radiothérapie Oncologique) november 2007 Parigi, *Premio Poster*

Abilitazione I Fascia Settore Concorsuale 06/I1 Diagnostica per Immagini, Radioterapia e Neuroradiologia con validità 02/10/2018-02/10/2024.

Membro della Radiobiology Committee della società Europea di Radioterapia ESTRO per l'anno 2022.

Coordinatore del gruppo di studio di Radioterapia Metabolica dell'Associazione Italiana di Radioterapia Oncologica (AIRO) per gli anni 2017-2019; Vice Coordinatore del gruppo di studio di Radioterapia Metabolica dell'Associazione Italiana di Radioterapia Oncologica (AIRO) dal 2014 al 2016; Consigliere del gruppo di studio di Radioterapia Metabolica dell'Associazione Italiana di Radioterapia Oncologica (AIRO) per il biennio 2011-2013.

Presidente dell'Associazione Italiana di Radiobiologia (AIRB) per il biennio 2019-2020; Membro del Consiglio Direttivo dell' Associazione Italiana di Radiobiologia (AIRB) dal 2014 al 2018

Membro del Consiglio Direttivo della Federazione Italiana delle Società Mediche dell'Area Radiologica (FIDESMAR) per il biennio 2019-2020.

Membro del Consiglio Direttivo della Federazione Italiana Ricerche sulle Radiazioni (FIRR) per il biennio 2019-2020

Direttrice del Radiobiology Premeeting Course “Complex tissue interactions in late effects” , 2nd ESTRO Forum, Ginevra 18 Aprile 2013.

Autrice di articolo selezionato da ASTRO (American Society for Radiotherapy & Oncology) per l’offerta di crediti ECM nel 2011 (“Association between Genetic Polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT Genes and Radiosensitivity in Breast Cancer Patients” Mangoni et al, IJROBP 2011; 81: 52-58).

Principal investigator di progetto di ricerca finanziato ITT (Istituto Toscano Tumori) Grant proposal 2013 dal titolo “Evaluation of effect of PARP inhibitors with or without irradiation in preclinical of soft-tissue sarcomas”

Presidente del XXX Congresso Nazionale AIRO, XXXII Congresso Nazionale AIRB, XI Congresso Nazionale AIRO Giovani, convegno virtuale, 9-12 dicembre 2020

Membro del Radiobiology SAG (Scientific Advisory Group) per ESTRO 2022

Coinvolta in numerosi progetti di ricerca finanziati nazionali ed internazionali, Partecipante come relatore su invito a conferenze nazionali e internazionali, Partecipante come docente a corsi, Partecipante come moderatrice a conferenze nazionali e internazionali

Membro del Board Editoriale di Journal of Tumors dal 2013, World Journal of Clinical Oncology dal 2015, Clinics in Oncology dal 2016, Cancer Research Journal dal 2018, Annals of Sarcoma Research & Clinical Practice dal 2018, Revisore per riviste internazionali

Autrice di oltre 70 pubblicazioni su riviste internazionali con h-index 21.

Docente per il SSD Med36 all’Università degli studi di Firenze e docente di Radioterapia e Radiobiologia a Master dell’Università degli Studi di Brescia, dell’Università La Sapienza e dell’Università Cattolica

Firenze 03/11/2021

Monica Mangoni



ANDREA MORANDI

Department of Experimental and Clinical Biomedical Sciences
University of Florence
Viale Morgagni, 50
50134 Florence (ITALY)
e-mail: andrea.morandi@unifi.it
Lab website: <https://www.sbosc.unifi.it/vp-326-gruppo-morandi.html>

PERSONAL INFORMATION

City, Country of Birth: Bagno a Ripoli (Florence) Italy
Citizenship: Italian
Languages: Italian, English, French

APPOINTMENTS/AFFILIATIONS

1 Dec 2021 Associate Professor of Biochemistry at University of Florence (UniFi)
2018-2021 Assistant Professor of Biochemistry at UniFi
2016-2018 Fondazione Veronesi Postdoctoral fellowship at UniFi
2013-2015 Postdoc at UniFi funded by Fondazione Italiana Ricerca Cancro (FIRC)
2010-2013 Postdoc at ICR (Institute of Cancer Research, London, UK)
2010-2012 Tutor in Cell Biology at Imperial College of London (UK).
2007-2008 Visiting PhD student at ICR
2007-2009 PhD student at UniFi
2004-2006 Research intern at the *Dipartimento di Patologia e Oncologia Sperimentali* at UniFi

EDUCATION

2010 PhD in Experimental and Clinical Oncology, UniFi
2006 Laurea Magistrale in Medical Biotechnologies, 110/110 cum laude at UniFi
2004 Laurea in Biotechnologies, 110/110 cum laude at UniFi

MEMBERSHIPS AND EDITORIAL ACTIVITY

Member of the editorial board of the following journals:

Editorial Board - Scientific Reports; 2017-

Associate Editor - BMC Cancer; 2017-

Associate Editor - Hormones and Cancer; 2017-

Associate Editor in Molecular and Cellular Oncology - Frontiers; 2019-

Guest Associate Editor in Cancer Metabolism - Frontiers; 2019-

Editorial Board - MDPI - Cancers; 2020-

Editorial Board - Taylor & Francis Online - Molecular and Cellular Oncology (MCO); 2020-

Faculty of the PhD Program in Biomedical Sciences, University of Florence
Board Member of "Gruppo Differenziamento e Trasformazione Neoplastica" of the
Biochemistry Italian Society

Member of the following Scientific Societies:

SIC (Società Italiana di Cancerologia), EACR (European Association Cancer Research), SIB (Società Italiana di Biochimica), ENBC (European Network for Breast Development and Cancer)

Active Journal reviewer for:

Cancer Research, Oncogene, Nature - Scientific Reports; Nature - Communications Biology, Trends in Molecular Medicine, Gene, Biomaterials, Cancer Letters, Carcinogenesis, Oncotarget, Hormones and Cancer, Epigenomics, Endocrine-Related Cancer, Cancer Medicine, NPJ Breast, Breast Cancer Research, BMC Cancer, BMC Biology, Frontiers in Oncology, Molecular Cancer Research, Molecular Cancer Therapeutics, Frontiers in Endocrinology, AIMS Medical Science, Cell Stress, International Journal of Cancer, The FEBS Journal, MDPI – Biology, Breast Cancer Research and Treatment, FASEB J, MDPI- Cancers,

Active referee for International Funding Agencies:

Genesis Oncology Trust (New Zealand), Estonian Research Council (Estonia), Breast Cancer Now (UK), FWF funding (Austria), DKFZ-MOST Israel-Cooperation (Germany-Israel)

HONORS AND AWARDS

2019: Chairman for the plenary section “Unraveling the role of metabolism in shaping cancer biology”. Metabolism Meets Function meeting.

2017: “Guido Berlucci Foundation Best Oral Presentation Prize” awarded during the International EACR-AACR-SIC Meeting.

2016: “Guido Berlucci Foundation Best Poster Prize” awarded during the Annual Meeting of the Italian Cancer Society.

2015: International Society for Cancer Metabolism (ISCaM) Young Investigator Award for the best oral communication.

2014: "Elena Capannini" Award for innovative anticancer therapy

2014: EACR (European Association of Cancer Research) Meeting Bursary awardee

2013: Morandi et al. Cancer Research paper was included in the highlights 10 exciting ICR discoveries from 2012/13

2013: AACR (American Association of Cancer Research) Scholar-In-Training SIC awardee

2012: Italian Foundation for Cancer Research 3 years fellowship awardee

2012: EACR “Targeted Therapies/Signaling Pathways Symposium” proffered paper awardee

2011: Cover of Trends in Molecular Medicine issue March 2011

GRANTS

2019-2024: AIRC Investigator Grant (role: Principal Investigator)

2019-2021: Gender Medicine - Excellence Department grant (role: Principal Investigator)

2021: Pezcoller Foundation-Società Italiana di Cancerologia 2021 (role: Scientific Supervisor of Dr Bacci, postdoctoral fellow of the lab)

2017-2020: AIRC-ECRF MultiUser Grant (role: Group Leader)

2018: Fondazione Umberto Veronesi postdoc fellowship

2017: Fondazione Umberto Veronesi postdoc fellowship

2016: Fondazione Umberto Veronesi postdoc fellowship

2012: AIRC/ FIRC 3-years fellowship

ORGANIZATION OF INTERNATIONAL MEETINGS:

2020: International Workshop Metabolism Meets Function (MMF) Firenze (postponed to June 2021 in virtual mode)

SCIENTIFIC IMPACT AND PRODUCTION

- 36 articles in ISI peer-reviewed journals
- 1 Chapters of books (in press BIOCHIMICA UMANA - Ed. Zanichelli)
- more than 50 congress communications.
- h-index: 24 (from Scopus database); 26 (from Google Scholar)
- 1502 total citations (Scopus 03 Nov 2021).

PUBLICATION LIST

1. Grillo E, Corsini M, Ravelli C, Zammataro L, Monti E, Bacci M, Morandi A, Presta M, Mitola S. Activation of VEGFR2 by R1051Q mutation rewires the energy metabolism of melanoma by increasing glutamine dependence. **Cancer Letters**. 2021 Feb *in press*

2. Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. **Trends Cancer**. 2020 Dec 3;. doi: 10.1016/j.trecan.2020.10.004. [Epub ahead of print] Review. PubMed PMID: 33281098. **Last author**

3. Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, Ledda-Columbano GM, Morandi A, Merlin S, Orrù C, Sanchez-Martin C, Fornari F, Gramantieri L, Parri M, Rasola A, Bellomo SE, Sebastian C, Follenzi A, Giordano S, Columbano A. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. **J Hepatol**. 2020 Jun;72(6):1159-1169. doi: 10.1016/j.jhep.2019.12.018. Epub 2020 Jan 15. PubMed PMID: 31954205.

4. Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, Migliaccio I, Malorni L, Chiarugi P, Morandi A. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib. **Cells**. 2020 Mar 10;9(3). doi: 10.3390/cells9030668. PubMed PMID: 32164162; PubMed Central PMCID: PMC7140692. **Last author**

5. Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A. Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. **Cell Rep**. 2019 Jul 2;28(1):104-118.e8. doi: 10.1016/j.celrep.2019.06.010. PubMed PMID: 31269432; PubMed Central PMCID: PMC6616584. **Last author**

6. Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, Raspollini MR, Magherini F, Rapizzi E, Masquelier J, Muccioli GG, Sonveaux P, Chiarugi P, Giannoni E. Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. **Oncogene**. 2019 Jul;38(27):5339-5355. doi: 10.1038/s41388-019-0805-7. Epub 2019 Apr 1. PubMed PMID: 30936458.
7. Taddei ML, Cavallini L, Ramazzotti M, Comito G, Pietrovito L, Morandi A, Giannoni E, Raugei G, Chiarugi P. Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy. **J Cell Physiol**. 2019 Jun;234(6):8274-8285. doi: 10.1002/jcp.27679. Epub 2018 Oct 30. Review. PubMed PMID: 30378132.
8. Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, Montagnani I, Raspollini MR, Serni S, Simeoni L, Giannoni E, Chiarugi P. Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis. **Oncogene**. 2019 May;38(19):3681-3695. doi: 10.1038/s41388-019-0688-7. Epub 2019 Jan 21. PubMed PMID: 30664688.
9. Ippolito L, Morandi A, Giannoni E, Chiarugi P. Lactate: A Metabolic Driver in the Tumour Landscape. **Trends Biochem Sci**. 2019 Feb;44(2):153-166. doi: 10.1016/j.tibs.2018.10.011. Epub 2018 Nov 22. Review. PubMed PMID: 30473428.
10. De Santis MC, Porporato PE, Martini M, Morandi A. Signaling Pathways Regulating Redox Balance in Cancer Metabolism. **Front Oncol**. 2018;8:126. doi: 10.3389/fonc.2018.00126. eCollection 2018. Review. PubMed PMID: 29740540; PubMed Central PMCID: PMC5925761. **Last author**
11. Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. **Nat Genet**. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. PubMed PMID: 29335542; PubMed Central PMCID: PMC5810912.
12. Morandi A, Indraccolo S. Linking metabolic reprogramming to therapy resistance in cancer. **Biochim Biophys Acta Rev Cancer**. 2017 Aug;1868(1):1-6. doi: 10.1016/j.bbcan.2016.12.004. Epub 2017 Jan 5. Review. PubMed PMID: 28065746. **First author**
13. Morandi A, Taddei ML, Chiarugi P, Giannoni E. Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. **Front Oncol**. 2017;7:40. doi: 10.3389/fonc.2017.00040. eCollection 2017. Review. PubMed PMID: 28352611; PubMed Central PMCID: PMC5348536. **First author**
14. Comito G, Pons Segura C, Taddei ML, Lanciotti M, Serni S, Morandi A, Chiarugi P, Giannoni E. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. **Oncotarget**. 2017 Jan 3;8(1):118-132. doi: 10.18632/oncotarget.9497. PubMed PMID: 27223431; PubMed Central PMCID: PMC5352046.

15. Andreucci E, Francica P, Fearn A, Martin LA, Chiarugi P, Isacke CM, Morandi A. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. **Oncotarget**. 2016 Dec 6;7(49):80543-80553. doi: 10.18632/oncotarget.11826. PubMed PMID: 27602955; PubMed Central PMCID: PMC5348339.
16. Morandi A, Giannoni E, Chiarugi P. Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk. **Trends Cancer**. 2016 Dec;2(12):736-746. doi: 10.1016/j.trecan.2016.11.001. Epub 2016 Dec 6. Review. PubMed PMID: 28741520. **First author**
17. Pietrobono S, Morandi A, Gagliardi S, Gerlini G, Borgognoni L, Chiarugi P, Arbiser JL, Stecca B. Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival. **J Invest Dermatol**. 2016 Oct;136(10):2059-2069. doi: 10.1016/j.jid.2016.06.610. Epub 2016 Jun 29. PubMed PMID: 27373978.
18. Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, Giannoni E, Schrader T, Pühr M, Chiarugi P, Taddei ML. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. **Oncotarget**. 2016 Sep 20;7(38):61890-61904. doi: 10.18632/oncotarget.11301. PubMed PMID: 27542265; PubMed Central PMCID: PMC5308698.
19. Kowalik MA, Guzzo G, Morandi A, Perra A, Menegon S, Masgras I, Trevisan E, Angioni MM, Fornari F, Quagliata L, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Chiarugi P, Rasola A, Columbano A. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. **Oncotarget**. 2016 May 31;7(22):32375-93. doi: 10.18632/oncotarget.8632. PubMed PMID: 27070090; PubMed Central PMCID: PMC5078020. **Co-First author**
20. Mattu S, Fornari F, Quagliata L, Perra A, Angioni MM, Petrelli A, Menegon S, Morandi A, Chiarugi P, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Columbano A. The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. **J Hepatol**. 2016 Apr;64(4):891-8. doi: 10.1016/j.jhep.2015.11.029. Epub 2015 Nov 30. PubMed PMID: 26658681.
21. Bacci M, Giannoni E, Fearn A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, Chiarugi P, Morandi A. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. **Cancer Res**. 2016 Mar 15;76(6):1615-26. doi: 10.1158/0008-5472.CAN-15-2038. Epub 2016 Jan 21. PubMed PMID: 26795347. **Last author**
22. Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, Richichi B, Raugei G, Wong N, Tang D, Chiarugi P. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. **Oncotarget**. 2015 Sep 15;6(27):24061-74. doi: 10.18632/oncotarget.4448. PubMed PMID: 26183399; PubMed Central PMCID: PMC4695170.
23. Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. Senescent stroma promotes prostate

cancer progression: the role of miR-210. **Mol Oncol**. 2014 Dec;8(8):1729-46. doi: 10.1016/j.molonc.2014.07.009. Epub 2014 Jul 21. PubMed PMID: 25091736; PubMed Central PMCID: PMC5528604.

24. Barbetti V, Morandi A, Tusa I, Digiacomio G, Rivero M, Marzi I, Cipolleschi MG, Bessi S, Giannini A, Di Leo A, Dello Sbarba P, Rovida E. Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. **Oncogene**. 2014 Aug 21;33(34):4359-64. doi: 10.1038/onc.2013.542. Epub 2013 Dec 23. PubMed PMID: 24362524; PubMed Central PMCID: PMC4141303. **Co-First author**

25. Rapizzi E, Ercolino T, Fucci R, Zampetti B, Felici R, Guasti D, Morandi A, Giannoni E, Giaché V, Bani D, Chiarugi A, Mannelli M. Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation. **Horm Cancer**. 2014 Jun;5(3):174-84. doi: 10.1007/s12672-014-0172-3. Epub 2014 Mar 5. PubMed PMID: 24595825.

26. Taddei ML, Giannoni E, Morandi A, Ippolito L, Ramazzotti M, Callari M, Gandellini P, Chiarugi P. Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. **Cell Commun Signal**. 2014 Apr 1;12:24. doi: 10.1186/1478-811X-12-24. PubMed PMID: 24690323; PubMed Central PMCID: PMC4022383.

27. Morandi A, Chiarugi P. Metabolic implication of tumor:stroma crosstalk in breast cancer. **J Mol Med (Berl)**. 2014 Feb;92(2):117-26. doi: 10.1007/s00109-014-1124-7. Epub 2014 Jan 24. Review. PubMed PMID: 24458539. **First author**

28. Morandi A, Isacke CM. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer. **Breast Cancer Res**. 2014 Jan 28;16(1):301. doi: 10.1186/bcr3608. PubMed PMID: 24467886; PubMed Central PMCID: PMC3978856. **First author**

29. Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. **Mol Cell Endocrinol**. 2013 Sep 5;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. Epub 2013 Jun 27. PubMed PMID: 23811235.

30. Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. **Cancer Res**. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6. PubMed PMID: 23650283; PubMed Central PMCID: PMC3686594. **First author**

31. Morandi A, Barbetti V, Rivero M, Dello Sbarba P, Rovida E. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. **PLoS One**. 2011;6(11):e27450. doi: 10.1371/journal.pone.0027450. Epub 2011 Nov 9. PubMed PMID: 22096574; PubMed Central PMCID: PMC3212567. **First author**

32. Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. **J Biol Chem**. 2011 May 13;286(19):17292-302. doi: 10.1074/jbc.M110.168500. Epub 2011 Mar 22. PubMed PMID: 21454698; PubMed Central PMCID: PMC3089571.

33. Morandi A, Plaza-Menacho I, Isacke CM. RET in breast cancer: functional and therapeutic implications. **Trends Mol Med.** 2011 Mar;17(3):149-57. doi: 10.1016/j.molmed.2010.12.007. Epub 2011 Jan 19. Review. PubMed PMID: 21251878.

First author

34. Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. **Oncogene.** 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7. PubMed PMID: 20531297.

35. Roviada E, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S, Dello Sbarba P. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. **J Immunol.** 2008 Mar 15;180(6):4166-72. doi: 10.4049/jimmunol.180.6.4166. PubMed PMID: 18322228.

36. Barbetti V, Gozzini A, Roviada E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. **Oncogene.** 2008 Mar 13;27(12):1767-78. doi: 10.1038/sj.onc.1210820. Epub 2007 Sep 24. PubMed PMID: 17891169.

CURRICULUM VITAE



PERSONAL INFORMATION

Address

Phone n.

Fax

E-mail

Nationality

Date of Birth

MEATTINI ICRO

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Italian

11/08/1980

WORK EXPERIENCE

2018-present

- Associate Professor of Radiation Oncology at Department of Experimental and Clinical Biomedical Sciences "M. Serio" – University of Florence, Florence, Italy

- Consultant Clinical Oncologist at AOU Careggi University Hospital, Florence, Italy

- Chair of the Multidisciplinary Oncology Group (GOM) in Breast cancer for Radiation Oncology (2012 - present)

- Head of Outpatient Clinics sub-Unit of Radiation Oncology Unit (2017-present)

2018-2024

National Scientific Qualification I level, Full Professor for Radiation Oncology (Scientific Disciplinary Sector (SSD) MED/36)

2011-2018

Consultant Clinical Oncologist

AOU Careggi Hospital, University of Florence, Florence, Italy

Radiation Oncology Unit, Oncology Department

2010-2011

AOU Careggi, University of Florence, Florence, Italy

Radiation Oncology Unit, Oncology Department

Research fellowship

Topic "Evaluation of genetic predisposition to induced radio toxicity". Supervisor: Prof. Giampaolo Biti

EDUCATION AND TRAINING

2017 Nov-2019 Mar

European Organisation for Research and treatment of Cancer (EORTC)

Early Career Investigators (ECI) Leadership Program for the management of Clinical Research in Oncology

2016-2018

University of Brescia, Brescia, Italy

II Degree Master on "Oncologic Drugs and Radiotherapy"

Dissertation topic "Hypofractionation in young breast cancer patients"

Supervisor: Prof. Stefano M. Magrini

2005-2009

University of Florence, Florence, Italy

Postgraduate Degree in Radiation Oncology. Dissertation topic "Breast cancer in patients treated for Hodgkin lymphoma: University of Florence experience".

Supervisor: Prof. Giampaolo Biti.

70/70 cum Laude

2008-2009

Royal Marsden Hospital, London (UK)

Fellowship Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada.

2005-2006

University of Florence, Florence, Italy

Department of Clinical Physiopathology

Professional referent. Topic: "Risk-assessment in Radiotherapy". [European project n. LSHC-CT-2004-503564 of Sixth Program MAESTRO (Advanced Methods and Equipment for Simulation and Treatment in Oncology Radiology)].

1999-2005

University of Florence.

Medical degree. Dissertation topic "Localized prostate cancer treated with intensity-modulated radiation therapy (IMRT)" Supervisor: Prof. Giampaolo Biti.

110/110 cum Laude

1994-1999

"N. Rodolico" High School, Florence, Italy.

Scientific High school degree.

100/100.

PERSONAL SKILLS

MOTHER TONGUE(S)

ITALIAN

FOREIGN LANGUAGE(S)

ENGLISH

UNDERSTANDING

• Reading

C1

• Listening

C1

SPEAKING

• Spoken interaction

C1

• Spoken production

C1

WRITING

C1

SPANISH

UNDERSTANDING

• Reading

B2

• Listening

B2

SPEAKING

• Spoken interaction

B2

• Spoken production

B2

WRITING

B2

SCIENTIFIC PUBLICATIONS

SCIENTIFICS AND EDUCATIONAL ACTIVITIES

Author of more than 190 peer-reviewed scientific publications in international journals, available at: <https://www.ncbi.nlm.nih.gov/pubmed/?term=meattini+i>
h-index: 24

Organization and participation as a speaker at national and international scientific conferences.

- Local Organizing Committee of the XVII National Congress of the Italian Association of Radiotherapy Oncology (AIRO) 2007, Florence, Italy.
- Invited speaker. XXII AIRO National Congress. Rome. Topic: "Radiotherapy after neoadjuvant system therapy: irradiation of the lymph node chains? cons ". 17-20/11/2012.
- Invited speaker. Workshop topic: "Advanced Breast Cancer: Evidence and Future Perspectives". Montecatini Terme, Italy. 24/05/2013.
- Invited speaker. 17th ECCO - 38th ESMO - 32nd ESTRO. European Cancer Congress: Reinforcing Multidisciplinary. Amsterdam, Netherlands.
- Invited speaker in the Roundtable Session on "How to Improve Career Opportunities for Young Oncologists Across Europe". 27/09/2013-01/10/2013.
- Invited speaker. XXIII AIRO National Congress. Taormina, Italy. "Toxicity in associations with systemic therapies". 26-29/10/2013.
- Report. ESTRO 33, Vienna, Austria. Selected oral communication in the session Clinical. Topic: "Breast cancer. Toxicity of APBI using IMRT versus whole breast irradiation: 3-year follow-up of a Phase III randomized trial with first (presenting author) I. Meattini. 4-8 / 04/2014.
- Invited speaker. Workshop topic: "Aggressive disease and indolent disease in advanced stage breast cancer". Pontedera, Italy. 06/19/2014.
- Invited speaker. Workshop topic: "Metastatic breast cancer therapy: role of anthracyclines", Pisa, Italy. 08/10/2014.
- Invited speaker. Workshop topic: "Building the best therapeutic program for the BC+ HR+/HER2-patient", Montecatini, Italy. 31/10/2014.
- Invited speaker. XXIV AIRO National Congress. Padua, Italy. "Wide Angle in Oncological Radiotherapy 2014". 9-11/11/2014.
- Invited speaker. Topic: "Consensus on the new indication in the eribulin as second line therapy ", Reggio Emilia. 03/03/2015.
- Report. 3rd ESTRO Forum, Barcelona, Spain. Presentation as a poster discussion in the Clinical session. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomized trial with first (presenting author) I. Meattini. 24-28 / 04/2015.
- Consensus Conference speaker. Topic: from the practice of "follow up" to the culture of "survivorship care", organized by the Italian Association of Medical Oncology (AIOM). Rome, 10-11/09/2015.
- Invited speaker. XXV AIRO National Congress. Rimini, Italy. Symposium "Breast reconstruction and radiotherapy implications". 7-10/11/2015.
- Invited speaker. V AIRO ZOOM Journal Club 2015, Bologna, Italy. 19/02/2016.
- Invited speaker. Workshop Topic: "HER2 determination" amplification methods. AOUC Florence, Italy. 26/02/2016.
- Invited speaker. Workshop topic: "The Breast Unit as a model of care for gender medicine in the AOU Careggi", AOUC Florence, Italy. 08/03/2016.
- Invited speaker. "HER2 positive breast carcinoma: Highlights and perspectives". AOU Careggi Florence, Italy. 13/04/2016.
- Invited speaker. "We Breast". Workshop topic: "Treatment of HR +/HER2 metastatic breast cancer in postmenopausal patients: from literature to clinical practice. Chemotherapy and hormone therapy". Prato, Italy 14/06/2016.
- Invited speaker. Advisory Board. Topic: "Treatment of patients with ER + HER2 metastatic breast cancer with Everolimus plus Exemestane: sharing of clinical and practical aspects to optimize treatment and management of patients". Antignano (Livorno), Italy. 27/06/2016.
- Invited speaker. Sustainability forum and opportunities in the health sector. Roundtable "The new frontiers in oncology". Stazione Leopolda, Florence, Italy. 23/09/2016.
- Invited speaker. Workshop Topic: "The Government of Pharmaceutical Innovation: Models of Sustainable Management of Innovative and High Cost Oncology Drugs". Istituto Toscano Tumori, Florence, Italy. 27/09/2016.
- Scientific Commission of the XXVII and XXVIII National Congress of the Italian Association of Radiotherapy Oncology (AIRO). Rimini, Italy 2017-2018.
- Invited speaker. XXVI AIRO National Congress. Symposium: "Innovative drugs in breast cancer".

Rimini, Italy. 30/09/2016 - 02/10/2016.

- Invited speaker. Conference "Primary therapy in breast cancer". Oncological Tuesdays of AIOM Toscana. Pisa, Italy. 04/10/2016.
- Invited speaker. Senological diagnostics seminary with interactive presentation. Topic: "Disease recovery: diagnosis and biological meaning. Utilities and limits of follow-up". Florence, Italy. 17-20/10/2016.
- Invited speaker. Itinerary section AIRO "Consensus for the irradiation of the mammary lymph node stations", Ospedale dell'Angelo di Venezia Mestre, Italy. 21/10/2016.
- Invited speaker. Brescia Meetings in Radiation Oncology. "International Research projects in cardio-oncology: focus on breast cancer". Brescia, Italy. 17-18 /11/2016.
- Report. ECCO 2017. Amsterdam, Netherlands. Proffered Paper Session: "Breast Cancer". Oral Presentation in a Proffered Paper Session. IMRT-Florence phase 3 trial: "Health-related quality of life analysis from the accelerated partial breast irradiation". 29/01/2017.
- Invited speaker. "Advanced Breast Cancer HR +: HER2- versus HER2 +. Open questions. BreastIng Work: aBC HR + / HER2 - an evolving panorama". Camogli, Italy 31/03/2017 - 01/04/2017.
- Invited speaker. Topic: "Lecture on External beam partial irradiation". ESTRO 36, Vienna, Austria. 5-9 /05/2017.
- Invited speaker. Topic: "Management of the patient with metastatic breast cancer". Pisa, Italy 11 May 2017.
- Consensus conference. Topic: "In situ carcinoma of the breast". Catania, Italy. 18-20/05/2017.
- Invited speaker. Topic: "Update Course in Cardio-Oncology". Pietrasanta, Italy. 15/09/2017.
- Invited speaker. Topic: "Metastatic breast carcinoma with positive hormone receptors. Which clinical entity?". Bergamo, Italy. 22-23/09/2017.
- Invited speaker. European Society for Radiation Oncology (ESTRO) and European Organization for the Research and Treatment of Cancer (EORTC). Speaker at the Annual Meeting of the Korean Society for Radiation Oncology (KOSRO). Seoul, Korea. 13/10/2017.
- Executive Committee of the IX edition of the Congress in Senology (AIS). Florence, Italy. 8-10/11/2017.
- Invited speaker. Topic: "Highlights in Radiotherapy. What news from the 2017 International Congresses"? "Il Cardello" Radiological Research Center. Rome, Italy. 25/01/2018.
- Executive Committee and Expert Board of the "2nd Think Tank meeting on research challenges in breast cancer", endorsed by ESTRO Assisi, Italy 1-3/03/2018.
- Local Organizer of the Spring Meeting of the Oncology Radiotherapy Group (ROG) of the European Organization for Cancer Research and Treatment (EORTC). Florence, Italy 11-13/03/2018.
- Invited speaker. Panel of Experts. 11th European Breast Cancer Conference (EBCC). Multidisciplinary Team in the Real-World session on "Young HER2 Negative Patients with Breast Cancer". Barcelona (Spain). 21-23/03/2018.
- ESTRO Conference 37, selected Oral Communication on: "DCIS treated with breast conservative surgery and radiotherapy: a national multicentre experience". Barcelona (Spain). 20-24/04/2018.
- Invited speaker. meeting "I se ed i ma del trattamento del carcinoma mammario metastatico ER+/HER2-". Ferrara, 11-12 May 2018.
- Invited Speaker. Brescia Meetings in Radiation Oncology "Immunity, drugs, radiation: from biology to contemporary clinical oncology". Brescia, 20-21 September 2018.
- Advisory Board coordinator. Corso ECM "Help Desk in aBC. Share the clinical experience". Firenze, 5 October 2018.
- Advisory Board. Breast Cancer Expert Meeting. Pisa, 13 November 2018.
- Invited Speaker. Annual Meeting Swedish Breast Medical Oncologist, Brostnokologisk Forening (BOF). Hesselby Slott, Vallingby, Stockholm (Sweden). 23-25 January 2019.
- Panel of Experts. Breast Surgery Toolbox – Hirslanden Klinik St. Anna Brustzentrum (ESTRO representative). "A consensus and toolbox to improve breast conservation rates and to guide axillary management after preoperative systemic therapy (PST)". Luzern (Switzerland). 8 February 2019.
- Invited Speaker. Meeting "Focus sulla chirurgia oncologica e ricostruttiva della mammella". Pisa, 11-12 April 2019.
- Invited Speaker. ESTRO 38 Annual Meeting. SP-0463 Towards less radiotherapy in breast cancer treatment. Milan, 27-30 April 2019.
- Executive Committee and Invited Speaker. XI Edition Biannual Meeting "Attualità in Senologia (AIS)". Firenze, 6-8 November 2019.
- Invited Speaker. VIII Breast Surgery Workshop. "Ductal carcinoma in situ of the breast".

Aarhus, 21-23 May 2019.

- Panel of Experts. III Skagen meeting. Skagen, 4-6 June 2019.
- Advisory Board. "HR+ 2020, Il carcinoma mammario avanzato in alta risoluzione". Firenze, 21 June 2019.
- Invited Speaker. 29th Residential Course "Modern Radiotherapy, time issues and new drugs". Roma, 21-23 October 2019.
- Invited Speaker. XXI Congress of the Brazilian Society of Radiotherapy. Rio de Janeiro (Brasil), 23-27 October 2019.
- Invited Speaker. ESMO Breast Cancer Virtual Meeting. "Is cardiac damage still relevant? And how can be avoided?". Virtual, 23-24 May 2020.
- Invited Speaker. Biannual Meeting 12th European Breast Cancer Conference (EBCC-12) (virtual). European Society for Radiotherapy & Oncology (ESTRO) - State of the Art in Radiation Oncology 2020. The best treatment in breast cancer radiotherapy 3D vs. IMRT. Virtual, 2-3 October 2020.
- Invited Speaker. Breast Turkish International Meeting Breastambul (hybrid/virtual). Istanbul, virtual, 17-18 October 2020.
- Invited Speaker. ESTRO40 Annual Meeting (virtual). 28 Nov – 1 Dec 2020.
- Invited Speaker. World Congress of Brachytherapy 2020 (virtual). Debate: Partial Breast Irradiation with 1-3 fractions. Virtual, 6-8 May 2021.
- Invited Speaker. Highlights St. Gallen Breast Cancer Conference 2021. Webinar, 28 May 2021.
- Invited Speaker. MORE TIME MORE LIFE. "Advanced Breast Cancer HR+ HER2-, dagli studi alla pratica clinica: gli inibitori CDK4/6 sono davvero tutti uguali?". Webinar, 2 July 2021.
- Invited Speaker. Senoforum Accademia di Senologia Umberto Veronesi. 15-16 July 2021.
- Invited Speaker. ESTRO41 Annual Meeting. Session: New endpoints for early breast cancer - Less is more? Presentation title: Health-related quality of life - Primary or surrogate endpoint? Madrid, 27-31 August 2021.
- Faculty member and Speaker. ESMO Virtual Preceptorship on Cancer Care in Elderly Patients. Radiotherapy in older patients. 2-3 September 2021.
- Faculty. Focus Group CNAO: Patologie mammarie. Webinar, 21 September 2021.
- Invited Speaker. Webinar ECM FAD "Il meraviglioso mondo dei PARP inibitori: dalla biologia molecolare alla pratica clinica". Webinar, 23 September 2021.
- Faculty member and Invited Speaker. Breastics24h Breast Oncoplastic. Oncoplastic Multidisciplinary Board Meeting. Webinar, 25 September 2021.
- Invited Speaker and Faculty. ESSO Advanced Course on Breast Cancer Surgery. Live Virtual Course, 24 November 2021.

Management, organization and participation in the activities of national and international research groups.

- Co-Chair of the Inter-regional Section Tosco-Umbra of the Italian Association of Radiotherapy Oncology (GTUOR). Biennium 2013-2015.
- Co-Chair of the Breast Cancer Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Biennium 2014-2016.
- Radiation Oncology Group (ROG) and the Breast Cancer Group (BCG) of the European Organization for Cancer Research and Treatment (EORTC). 2014-today.
- Co-Chair of the Breast Working party (BWP) of the ROG of the EORTC. 2013-2018.
- Selected for the program promoted by the European Organization for Cancer Research and Treatment (EORTC): Early Career Investigator (ECI) EORTC Program. 2017-2019.
- European Organization for Research and Treatment of Cancer (EORTC) - Radiation Oncology Group (ROG) -Disease Oriented Groups Junior Representative (JRDR) for Breast Cancer. March 2018-2020.
- Founding Partner and Chair of the National / International Multi-Center Study Group "Clinical Oncology Breast Cancer Group - Group of Clinical Oncology of Breast Cancer" (COBCG). March 2018-today.
- Member the Italian College of Senologists. 2016-2020.
- Member of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). 2006-today.
- Member of the Italian Association of Radiobiology (AIRB).
- Member of European Society for Radiation Oncology (ESTRO) since 2012
- Member of the European Organization for Research and Treatment of Cancer (EORTC) since

2014.

- Writing Committee of Breast Cancer AIRO Italian Guideline. 2017-2018.
- Reviewer Committee of Breast Cancer AIRO Italian Guideline. 2019-2020.
- Reviewer Committee of Breast Cancer Italian Guideline of the Medical Oncology Italian Association (AIOM). 2018-2020.
- Executive Committee of the Biannual Meeting "Attualità in Senologia". Florence. 2019 and 2021.
- Scientific Committee of SenoNetwork. 2020-2022.
- Scientific Committee of the National Meeting AIRO. 2019-2021.
- Chair of the Breast Cancer Group of AIRO. 2020-2022.
- Member of the Radiation Oncology Scientific Council (ROSC) EORTC. 2020-2022.
- Member of the ESTRO Clinical SAG Committee. ESTRO Meeting 2020 (virtual), ESTRO Meeting 2021 (Madrid), and ESTRO Meeting 2022 (Copenhagen).

Responsibility and coordination of scientific works and research

- Co-Principal Investigator. APBI-IMRT-Florence (NCT02104895) phase III trial. Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation. Institution: University of Florence, Italy.
- Sub-Investigator. PERTAIN Trial (Hoffmann-La Roche) A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Hormone Receptor-Positive, HER2-positive Metastatic Breast Cancer patients. NCT01491737.
- Sub-Investigator. SAFE HER trial (Hoffmann-La Roche). A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients with Early HER2-Positive Breast Cancer (SafeHer). NCT01566721.
- Sub-Investigator. BELLE3 trial (Novartis). Randomized, double-blind, placebo-controlled, Phase III trial with BKM120 in combination with fulvestrant in postmenopausal patients with HER2-negative hormone receptor positive, locally advanced or metastatic carcinoma treated with aromatase inhibitors and presented progression during or after therapy with a regimen containing an mTOR inhibitor.
- Sub-Investigator. SAFE phase III trial (NCT02236806). Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo) Adjuvant Anthracyclines and / or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial. Institution: University of Florence, Italy.
- Sub-Investigator. GIM13 AMBRA (Oncotech Consortium). Longitudinal cohort study on the therapeutic choices of HER2-negative metastatic breast cancer in Italian clinical practice.
- Sub-Investigator. GIM10 CONSENT (IRCCS AOU San Martino-IST). Phase III clinical study comparing the concomitant and sequential administration of CT and AI as adjuvant treatment of postmenopausal patients with hormone-sensitive breast cancer.
- Sub-Investigator. SANDPIPER Trial (Hoffmann-La Roche). SANDPIPER Study: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy. NCT02340221.
- Sub-Investigator. BONADIUV phase II trial (NCT02616744). A Single - blind, Randomized, Placebo - controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial. Institution: University of Florence, Italy.
- Sub-Investigator. GIM16 FEVEX (Consorzio Oncotech). Fulvestrant followed by everolimus plus exemestane vs exemestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR +) ad human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.
- Sub-Investigator. SINODAR ONE trial (Humanitas Research Foundation - Rozzano, Milan). T1-T2 mammary carcinoma: comparison of excision and preservation of axillary lymph nodes in the presence of metastases to the sentinel lymph node.
- Sub-Investigator. PAINTER trial (Medical Oncology of the Fatebenefratelli Hospital) .PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment. NCT02864030.
- Co-Investigator. LUCY Study: Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1 / 2 Mutations. Eudract Code: 2017-001054-34.
- Co-Investigator. Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39146.

- Co-Investigator. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Atezolizumab In Combination With Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer "(F. Hoffmann -La Roche Ltd). Protocol Number MO39193. Eudract Number 2016-005119-42.
- Co-Investigator. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of atezolizumab (Anti-PD-L1 antibody) In Combination With Paclitaxel compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39196 Eudract Number 2016-004024-29.
- Co-Investigator. Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer (Pallas). Alliance Foundation Trials, Llc. Clinicaltrials.Gov Identifier: Nct02513394.
- Co-Investigator. Non-Interventional Study To Characterize The Real World Treatment Patterns And Outcomes Of Women With ER+, HER2- Advanced Or Metastatic Breast Cancer In Italy (Pfizer). Protocol Number A5481031.
- Co-Investigator. Complement-1: "An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR +) HER2- negative (HER2) advanced breast cancer (BC) with no prior hormone therapy for advanced disease". Eudract Code: 2016-003467-19.
- Principal Investigator. Phase III trial (EUROPA trial). ExclUsive endocRine therapy Or Partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 non-inferiority trial. ClinicalTrial.gov Identifier NCT04134598. Institution: University of Florence.

Scientific responsibility for national and international projects.

- Professional Research Assign at the Department of Clinical Physiopathology of the University of Florence, Italy. Topic: "Risk-assessment in Radiotherapy". European project no. LSHC-CT-2004-503564 - VI Program MAESTRO (Methods and Advanced Equipment for Simulation and Treatment in Radio Oncology). 10/1/2005 - 01/03/2006.
- Research fellowship Topic "Evaluation of genetic predisposition to induced radio toxicity" (*DAI Oncology, SODC Radiotherapy*) of the Department of Clinical Pathophysiology of the University of Florence, Italy. (2009 Regional Health Research Grant). 01/07/2010 - 30/07/2011.

Participation in editorial committees of magazines and editorial series

- Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online)
- Case Reports in Pathology (ISSN: 2090-6781)
- Translational Cancer Research (Translator Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803)
- Subject Editor (Radiation Therapy) Critical Review in Oncology/Hematology (ISSN 1040-8428).

Reviewer for Scientific Journals

- Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online).
- Case report in Pathology (ISSN: 2090-6781).
- BMC Cancer (ISSN: 1471-2407).
- Onkologie (ISSN: 1423-0240).
- Medical radiology (ISSN: 1826-6983).
- Tumor Biology (Tumor Biology Tumor Markers, Tumor Targeting and Translational Cancer Research, ISSN: 1010-4283).
- Clinical Breast Cancer (ISSN: 1526-8209).
- Urologic Oncology (ISSN: 1078-1439).
- The Breast (ISSN: 0960-9776).
- Future Oncology (ISSN 1479-6694).
- Radiotherapy and Oncology (ISSN 0167-8140)
- Critical Review in Oncology/Hematology (ISSN 1040-8428)

Assignments in University teaching courses and research institutes

- Fellowship. Oncology Radiotherapy Unit - Radiation Oncology Unit, Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada from 01.10.2008 to 31.03.2009. Clinical activity at the "Royal Marsden Hospital" (RMH), London (UK) and research activity at The Institute of Cancer Research (ICR), London, Sutton (UK). Consulting at the Chelsea and Sutton institute of the RMH specialized in lung and brain cancer (Prof. Michael Brada). Outpatient clinical activity at the Sutton site of the specialized RMH in hematological malignancies (Prof. Alan Horwich). Discussion and participation in Multi-Disciplinary Team (MDT) of lung cancer (Sutton's RMH site) and cerebral cancer (St. George Hospital, Wimbledon, London).
- Frontal teaching and student tutor in Master's Degree course, Medical School and Three-year Degree Course in Medical Radiology Techniques.
- Frontal teaching and mentoring in specialized training Specialization school in Radiation Oncology AOUC Florence.
- Thesis co-supervisor (Supervisor Prof. Lorenzo Livi) Medical School, University of Florence, Italy.
- Local Speaker of the Advanced Course on Multidisciplinary Breast Cancer Treatment of the European Society of Radiotherapy Oncology (ESTRO), ESTRO Teaching Course on the Multidisciplinary Management of Breast Cancer 2015, ESTRO School of Radiation Oncology.
- Teacher of the ESTRO Teaching Course on Accelerated partial Breast Irradiation. 2020-today.

University of Florence academic teaching courses:

Aa. 2018/2019 e 2019/2020:

Tecniche di Radiologia medica, per Immagini e Radioterapia

- TECNICHE DI DIAGNOSTICA PER IMMAGINI II (RADIODIAGNOSTICA) [B019930]
- TECNICHE DI DIAGNOSTICA PER IMMAGINI II (APPLICATE ALLA TC) [B024640]
- TECNICHE DI DIAGNOSTICA PER IMMAGINI II (APPLICATE ALLA TC E AGLI STUDI PEDIATRICI) [B029359]
- TECNICHE DI DIAGNOSTICA IN RADIOLOGIA GENERALE - SENOLOGIA E INTERVENTISTICA [B029341]

Medicina e Chirurgia (LM)

- DIAGNOSTICA PER IMMAGINI (CORSO INTEGRATO) [0090435]
- SPECIALITA' MEDICHE (C.I.) [B014289]
- SPECIALITA' MEDICHE (C.I.) [B011618]

Infermieristica

- PROCESSI E PERCORSI DIAGNOSTICO-TERAPEUTICO-ASSISTENZIALI [B017162]

Aa. 2020/2021:

Assistenza Sanitaria

SCIENZE DELLA PREVENZIONE [B020074]

SCIENZE DELLA PREVENZIONE [B030150]

Ostetricia

PROMOZIONE DELLA SALUTE E DELLA SICUREZZA [B030999]

Infermieristica

PROCESSI DIAGNOSTICI E TERAPEUTICI [B030242]

Medicina e Chirurgia

DIAGNOSTICA PER IMMAGINI (CORSO INTEGRATO) [0090435]

Clinical activity

Main clinical care responsibilities (Radiation Oncology Unit - AOU Careggi Firenze, Prof. Lorenzo Livi):

- Clinical, diagnostic, therapeutic and follow-up phases; participation in MDT, concomitant therapies (radiotherapy, chemotherapy, molecular therapies), supportive and palliative therapies;
- Referent Breast Cancer MDT of the AOU Careggi as Clinical Oncologist/ Radiation Oncologist;

- Day-Hospital activities: chemotherapies and molecular therapies in primary, adjuvant and metastatic settings of cancer patients; supportive therapy; management of revaluations under treatment; participation in internal, national and international clinical trials (sponsored and academics);
- Activities in the radiotherapy planning unit: management of early therapy and tolerance consulting; linear accelerators, tomotherapy, GammaKnife, CyberKnife; use of treatment plan systems for the contouring and planning of standard, conformational, stereotactic, IMRT, VMAT (XiO, Odyssey, Pinnacle, Monaco) treatments;
- Knowledge of record and verify systems; use of PACS systems for image management; use of patient positioning verification systems and immobilization systems.

Florence, Italy, 08/11/2021
Prof. Icro Meattini

